Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Gentiva Health Services (NASDAQ:GTIV), a provider of home health and hospice care within the United States, soared by as much as 14% earlier this morning after confirming that it had received another buyout offer from an undisclosed suitor.
So what: According to Gentiva, the buyer, which it's refused to name but described as "a recognized owner, operator, and investor in the sector", is willing to purchase Gentiva for $635.5 million, or $17.25 per share. This would be superior to Kindred Healthcare's (NYSE:KND) recently increased offer which currently stands at $16 per share and has been previously upped twice already. Gentiva's board of directors noted that it would consider the new proposal and advised shareholders against tendering their shares in favor of Kindred's $16 per share offer.
Now what: I'd personally like to know what company is crazy enough to bid Gentiva even higher. I do understand that Gentiva would help a larger suitor expand its geographic reach and could potentially help position a buyer for success over the next two to three decades as baby boomers begin to retire. However, Gentiva is also sporting a not so takeover friendly $1.1 billion in net debt and is likely going to be pinched by declining Medicare and Medicaid reimbursements as the Affordable Care Act pushes health-based businesses slowly away from relying on government funds. In other words, Gentiva's growth outlook isn't all that great and its debt only compounds those concerns, so the fight to buy it makes little sense to me. With shares once again trading above the stated offer price I'd suggest keeping your distance as I just don't see how any more blood can be squeezed out of this turnip.
Gentiva could offer a suitor plenty of potential, but compared to the opportunity presented by this revolutionary product, Gentiva would likely be eating dust!
The best health care investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.